Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: ITCA 650 (exenatide in osmotic mini-pump) continuously delivers exenatide subcutaneously for 3–6 months. Two doses of ITCA 650 were compared with placebo in patients with uncontrolled type 2 diabetes. RESEARCH DESIGN AND METHODS: This 39-week, phase 3, double-blind, placebo-controlled trial randomized 460 patients aged 18–80 years with glycated hemoglobin (HbA1c) 7.5–10% [58–86 mmol/mol] 1:1:1 to placebo, ITCA 650 40 μg/day, or ITCA 650 60 μg/day. Primary end point was change in HbA1c at 39 weeks. RESULTS: Least squares (LS) mean change from baseline HbA1c was −1.1% [−12.2 mmol/mol] and −1.2% [−13.2 mmol/mol] for ITCA 650 40 and 60 μg/day, respectively (P < 0.001 vs. placebo −0.1% [−1.3 mmol/mol]). In a prespecified analysis, greater HbA1c reductions occurred in patients not receiving sulfonylureas (SUs) versus those receiving SUs (−1.7% vs. −1.2% [−18.6 and −13.1 mmol/mol]). At week 39, HbA1c <7% [53 mmol/mol] was attained in 37%, 44%, and 9% of ITCA 650 40 μg/day, ITCA 650 60 μg/day, and placebo groups, respectively (P < 0.001 each dose vs. placebo). LS mean change from baseline body weight was −2.3 kg and −3.0 kg for ITCA 650 40 and 60 μg/day, respectively (P ≤ 0.015 vs. placebo −1.0 kg). Nausea was the most common adverse event (AE) and subsided over time. Discontinuation for gastrointestinal AEs occurred in 7.2% with ITCA and 1.3% with placebo. Most AEs associated with procedures to place and remove ITCA 650 were mild and transient. CONCLUSIONS: ITCA 650 significantly reduced HbA1c and weight compared with placebo and was well tolerated in patients with uncontrolled type 2 diabetes on oral antidiabetes medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 2×
“GLP-1 RAs are broadly recommended as add-on to monotherapy with metformin or in combination with multiple oral agents and insulin for patientswith poorly controlled diabetes (21,24).”
BackgroundSelf-citationThe Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988–2010
Stark Casagrande, S., Fradkin, J. E., Saydah, S. H., Rust, K. F., & Cowie, C. C. (2013) · Diabetes Care · doi:10.2337/dc12-2258 · Cited by 719
The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582
Self-citationNauck, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12591 · Cited by 429
Bettge, K., Kahle, M., Abd El Aziz, M. S., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12824 · Cited by 374 · cited 3×
“Glucagonlike peptide 1 receptor agonists (GLP-1 RAs) are considered effective therapeutic agents for the treatmentof type2diabetes (4) that lower glucose, promote weight loss, and have a low risk of hypoglycemia (5) due to their glucose-dependent effect on insulin secretion (6).”
ResultMedication Nonadherence in Diabetes
Egede, L. E., Gebregziabher, M., Dismuke, C. E., Lynch, C. P., Axon, R. N., Zhao, Y., & Mauldin, P. D. (2012) · Diabetes Care · doi:10.2337/dc12-0572 · Cited by 195
Alatorre, C., Fernández Landó, L., Yu, M., Brown, K., Montejano, L., Juneau, P., Mody, R., & Swindle, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12902 · Cited by 111
Wilke, T., Mueller, S., Groth, A., Berg, B., Fuchs, A., Sikirica, M., Logie, J., Martin, A., & Maywald, U. (2016) · Diabetes Therapy · doi:10.1007/s13300-015-0149-4 · Cited by 41
Thomsen, R. W., Baggesen, L. M., Søgaard, M., Pedersen, L., Nørrelund, H., Buhl, E. S., Haase, C. L., & Johnsen, S. P. (2015) · Diabetologia · doi:10.1007/s00125-015-3698-1 · Cited by 32
Research works printed but not linked: 15
- Breitscheidel, 2010, Economic impact of compliance to treatment with antidiabetes medication in type 2 diabetes mellitus: a review paper, J Med Econ, 13, 8, 10.3111/13696990903479199 · DOI · Paper page
- Palmer, 2016, Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis, JAMA, 316, 313, 10.1001/jama.2016.9400 · DOI · Paper page
- Yu, 2016, Liraglutide versus exenatide once weekly: persistence, adherence, and early discontinuation, Clin Ther, 38, 149, 10.1016/j.clinthera.2015.11.017 · DOI
- Rohloff, 2008, DUROS technology delivers peptides and proteins at consistent rate continuously for 3 to 12 months, J Diabetes Sci Technol, 2, 461, 10.1177/193229680800200316 · DOI
- Henry, 2013, A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes, Clin Ther, 35, 634, 10.1016/j.clinthera.2013.03.011 · DOI
- Henry, 2013, Randomized trial of continuous subcutaneous delivery of exenatide by ITCA 650 versus twice-daily exenatide injections in metformin-treated type 2 diabetes [published correction appears in Diabetes Care 2013;36:2559–2565], Diabetes Care, 36, 2559, 10.2337/dc12-2410 · DOI · Paper page
- Henry, 2014, Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes, J Diabetes Complications, 28, 393, 10.1016/j.jdiacomp.2013.12.009 · DOI · Paper page
- Kayaniyil, 2016, A network meta-analysis comparing exenatide once weekly with other GLP-1 receptor agonists for the treatment of type 2 diabetes mellitus, Diabetes Ther, 7, 27, 10.1007/s13300-016-0155-1 · DOI · Paper page
- Kim, 2007, Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes, Diabetes Care, 30, 1487, 10.2337/dc06-2375 · DOI · Paper page
- Htike, 2017, Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis, Diabetes Obes Metab, 19, 524, 10.1111/dom.12849 · DOI · Paper page
- Calvert, 2007, Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study, Br J Gen Pract, 57, 455
- Khunti, 2013, Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people, Diabetes Care, 36, 3411, 10.2337/dc13-0331 · DOI · Paper page
- Abdul-Ghani, 2015, Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial, Diabetes Obes Metab, 17, 268, 10.1111/dom.12417 · DOI · Paper page
- Rosenstock, 2015, Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin, Diabetes Care, 38, 376, 10.2337/dc14-1142 · DOI · Paper page
- Henry, 2016, Efficacy and tolerability of exenatide once weekly over 6 years in patients with type 2 diabetes: an uncontrolled open-label extension of the DURATION-1 study, Diabetes Technol Ther, 18, 677, 10.1089/dia.2016.0107 · DOI · Paper page
Cited by
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Brown, E., Heerspink, H. J. L., Cuthbertson, D. J., & Wilding, J. P. H. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00536-5 · Cited by 581
Glucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543
MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
Nauck, M. A., & Meier, J. J. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0566 · Cited by 254
The Origin and Understanding of the Incretin Concept
Rehfeld, J. F. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00387 · Cited by 102
Ruff, C. T., Baron, M., Im, K., O’Donoghue, M. L., Fiedorek, F. T., & Sabatine, M. S. (2022) · Nature Medicine · doi:10.1038/s41591-021-01584-3 · Cited by 102
Self-citationVosoughi, K., Atieh, J., Khanna, L., Khoshbin, K., Prokop, L. J., Davitkov, P., Murad, M. H., & Camilleri, M. (2021) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.101213 · Cited by 97
Incretins in obesity and diabetes
Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93
Vosoughi, K., Salman Roghani, R., & Camilleri, M. (2022) · Obesity Medicine · doi:10.1016/j.obmed.2022.100456 · Cited by 65
Rehfeld, J. F., Knop, F. K., Asmar, A., Madsbad, S., Holst, J. J., & Asmar, M. (2018) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2018.1530297 · Cited by 62
Zhang, Z., Zhang, Q., Tan, Y., Chen, Y., Zhou, X., Liu, S., & Yu, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1149328 · Cited by 46
Metadata
- Authors
- Rosenstock, J., Buse, J. B., Azeem, R., Prabhakar, P., Kjems, L., Huang, H., & Baron, M. A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-12-14
- Volume
- 41
- Issue
- 2
- Pages
- 333-340
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2774301756
- Cited by
- 53
- References
- 9
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- green
- Funders
- Intarcia Therapeutics, Inc.
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.